These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Generation of the membrane attack complex during haemodialysis: impact of classical and alternative pathway components. Hauser AC, Derfler K, Stockenhuber F, Janata O, Balcke P. Clin Sci (Lond); 1990 Nov; 79(5):471-6. PubMed ID: 2174314 [Abstract] [Full Text] [Related]
5. Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis. Brodeur JP, Ruddy S, Schwartz LB, Moxley G. Arthritis Rheum; 1991 Dec; 34(12):1531-7. PubMed ID: 1747138 [Abstract] [Full Text] [Related]
9. Complement activation during OKT3 treatment: a possible explanation for respiratory side effects. Raasveld MH, Bemelman FJ, Schellekens PT, van Diepen FN, van Dongen A, van Royen EA, Hack CE, ten Berge IJ. Kidney Int; 1993 May 20; 43(5):1140-9. PubMed ID: 8510394 [Abstract] [Full Text] [Related]
11. Pleural SC5b-9 in differential diagnosis of tuberculous, malignant, and other effusions. Hara N, Abe M, Inuzuka S, Kawarada Y, Shigematsu N. Chest; 1992 Oct 20; 102(4):1060-4. PubMed ID: 1395743 [Abstract] [Full Text] [Related]
12. Complement activation during CAPD. Young GA, Kendall S, Brownjohn AM. Nephrol Dial Transplant; 1993 Oct 20; 8(12):1372-5. PubMed ID: 8159307 [Abstract] [Full Text] [Related]
16. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement. Buyon JP, Tamerius J, Belmont HM, Abramson SB. Arthritis Rheum; 1992 Sep 20; 35(9):1028-37. PubMed ID: 1418018 [Abstract] [Full Text] [Related]
17. A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants. Flechner SM, Goldfarb DA, Fairchild R, Modlin CS, Fisher R, Mastroianni B, Boparai N, O'Malley KJ, Cook DJ, Novick AC. Transplantation; 2000 Jun 15; 69(11):2374-81. PubMed ID: 10868643 [Abstract] [Full Text] [Related]
18. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. Manzi S, Rairie JE, Carpenter AB, Kelly RH, Jagarlapudi SP, Sereika SM, Medsger TA, Ramsey-Goldman R. Arthritis Rheum; 1996 Jul 15; 39(7):1178-88. PubMed ID: 8670328 [Abstract] [Full Text] [Related]
19. Complement activation products in plasma after heart transplantation in humans. Vallhonrat H, Williams WW, Dec GW, Keck S, Schoenfeld D, Cosimi AB, Pascual M. Transplantation; 2001 May 15; 71(9):1308-11. PubMed ID: 11397968 [Abstract] [Full Text] [Related]
20. Activation of the complement system by different autologous transfusion devices: an in vitro study. Tylman M, Bengtson JP, Bengtsson A. Transfusion; 2003 Mar 15; 43(3):395-9. PubMed ID: 12675727 [Abstract] [Full Text] [Related] Page: [Next] [New Search]